Which is the preferred second‑generation Bruton tyrosine kinase inhibitor, acalabrutinib or zanubrutinib?

Zanubrutinib and acalabrutinib are considered equivalent in current guidelines, though emerging evidence suggests zanubrutinib may offer superior efficacy outcomes.

Guideline Recommendations

Both second-generation BTK inhibitors are listed with equal strength recommendations in the 2024 ESMO Clinical Practice Guidelines for chronic lymphocytic leukemia 1. The guidelines explicitly state:

• For relapsed/refractory CLL: "Acalabrutinib or zanubrutinib as continuous therapy [I, A]" - both receive the same level of evidence and grade of recommendation
• For first-line treatment: Both acalabrutinib [III, A] and zanubrutinib [III, A] are listed as equivalent options
• Both are preferred over ibrutinib due to superior cardiovascular safety profiles, particularly lower rates of atrial fibrillation and hypertension 1

The guidelines note that when selecting between them, clinicians should consider side-effect profiles, with acalabrutinib showing less atrial fibrillation and hypertension, and zanubrutinib showing less atrial fibrillation compared to ibrutinib 1.

Emerging Research Evidence Favoring Zanubrutinib

Despite guideline equivalence, recent high-quality research suggests zanubrutinib may have clinical advantages:

Relapsed/Refractory CLL

A 2025 matching-adjusted indirect comparison found zanubrutinib demonstrated significantly superior progression-free survival versus acalabrutinib (HR 0.68,95% CI 0.46-0.99, p=0.0448), with significantly higher complete response rates (OR 2.90,95% CI 1.13-7.43, p=0.0270) and a trend toward improved overall survival 2.

A 2025 network meta-analysis in high-risk relapsed/refractory CLL found zanubrutinib significantly reduced risk of progression or death compared to acalabrutinib (HR 0.55,95% CI 0.32-0.94), with numerical trends favoring zanubrutinib for overall survival 3.

Treatment-Naïve CLL

A 2026 indirect comparison with 6-year follow-up showed zanubrutinib trended toward improved PFS versus acalabrutinib (HR 0.76,95% CI 0.52-1.11), with significantly higher 72-month landmark rates for both PFS (risk difference 9.9%, 95% CI 3.0-16.9%) and OS (risk difference 8.8%, 95% CI 2.0-15.5%) 4.

Real-World Evidence

A 2026 real-world analysis of 473 patients found zanubrutinib demonstrated significantly longer treatment persistence than acalabrutinib (adjusted HR 0.50,95% CI 0.3-0.7, p<0.01), with 12-month treatment continuation rates of 83.3% versus 69.5%, and lower toxicity-related discontinuation (5.4% vs 10.7%) 5.

Pharmacologic Distinctions

Zanubrutinib achieves more complete and sustained BTK inhibition 6, 7:

• Maintains 100% median BTK occupancy in peripheral blood over 24 hours
• Achieves 94-100% BTK occupancy in lymph nodes
• Greater selectivity for BTK minimizes off-target kinase inhibition

Acalabrutinib maintains ≥95% median BTK occupancy over 12 hours but requires twice-daily dosing 8.

Clinical Decision Algorithm

For most patients with CLL requiring BTK inhibitor therapy:

1. First choice: Zanubrutinib based on:

   • Superior efficacy signals in indirect comparisons
   • Better real-world treatment persistence
   • Lower discontinuation rates
   • More complete BTK inhibition

2. Consider acalabrutinib when:

   • Zanubrutinib is unavailable or not covered by insurance
   • Patient preference for established therapy
   • Specific drug interactions favor acalabrutinib

3. Both are strongly preferred over ibrutinib in patients with:

   • Cardiovascular comorbidities
   • History of atrial fibrillation
   • Hypertension
   • Age ≥65 years

Important Caveats

• No head-to-head randomized trials directly compare zanubrutinib and acalabrutinib; all comparative data come from indirect analyses with inherent limitations
• Guidelines have not yet incorporated the most recent comparative effectiveness data
• Both agents require continuous therapy unless used in combination regimens
• Individual patient factors (comorbidities, drug interactions, access) may override general recommendations
• The efficacy differences, while statistically significant in some analyses, translate to modest absolute improvements that may not be clinically meaningful for all patients